Sahlberg KK - Search Results

1

Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø. Nunes-Xavier CE, et al. Among authors: sahlberg kk. Oncotarget. 2016 Feb 9;7(6):6891-901. doi: 10.18632/oncotarget.6902. Oncotarget. 2016. PMID: 26771843 Free PMC article.

2

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.

Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O. Sahlberg KK, et al. Among authors: sahlberg n. Mol Oncol. 2013 Jun;7(3):392-401. doi: 10.1016/j.molonc.2012.10.012. Epub 2012 Nov 24. Mol Oncol. 2013. PMID: 23253899 Free PMC article.

3

High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.

Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M. Leivonen SK, et al. Among authors: sahlberg kk. Mol Oncol. 2014 Feb;8(1):93-104. doi: 10.1016/j.molonc.2013.10.001. Epub 2013 Oct 11. Mol Oncol. 2014. PMID: 24148764 Free PMC article.

4

Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c.

Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK. Nygren MK, et al. Among authors: sahlberg kk. Br J Cancer. 2014 Apr 15;110(8):2072-80. doi: 10.1038/bjc.2014.113. Epub 2014 Feb 27. Br J Cancer. 2014. PMID: 24577056 Free PMC article.

5

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description.

Hongisto V, Aure MR, Mäkelä R, Sahlberg KK. Hongisto V, et al. Among authors: sahlberg kk. Genom Data. 2014 Jul 22;2:249-53. doi: 10.1016/j.gdata.2014.06.025. eCollection 2014 Dec. Genom Data. 2014. PMID: 26484103 Free PMC article.

6

Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer.

Lesurf R, Aure MR, Mørk HH, Vitelli V; Oslo Breast Cancer Research Consortium (OSBREAC); Lundgren S, Børresen-Dale AL, Kristensen V, Wärnberg F, Hallett M, Sørlie T. Lesurf R, et al. Cell Rep. 2016 Jul 26;16(4):1166-1179. doi: 10.1016/j.celrep.2016.06.051. Epub 2016 Jul 7. Cell Rep. 2016. PMID: 27396337 Free article.

7

LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer.

Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F; Oslo Breast Cancer Research Consortium (OSBREAC)SauerTorillGeislerJürgenHofvindSolveigBathenTone FBorgenElinEngebråtenOlavFodstadØysteinGarredØysteinGeitvikGry AarumKåresenRolfNaumeBjørnMælandsmoGunhild MariRussnesHege GSchlichtingEllenSørlieThereseLingjærdeOle ChristianSahlbergKristine KleiviSkjervenHelle KristineFritzmanBritt; Ulitsky I, Diederichs S, Wiemann S, Yakhini Z, Kristensen VN, Børresen-Dale AL, Yarden Y. Sas-Chen A, et al. EMBO Mol Med. 2016 Sep 1;8(9):1052-64. doi: 10.15252/emmm.201606198. Print 2016 Sep. EMBO Mol Med. 2016. PMID: 27485121 Free PMC article.

8

Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T; Oslo Breast Cancer Consortium (OSBREAC); Naume B, Borgen E, Mælandsmo GM. Egeland EV, et al. Breast Cancer Res Treat. 2017 Feb;162(1):127-137. doi: 10.1007/s10549-016-4096-1. Epub 2017 Jan 5. Breast Cancer Res Treat. 2017. PMID: 28058579

9

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response.

Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK. Jernström S, et al. Among authors: sahlberg kk. Breast Cancer (Dove Med Press). 2017 Mar 21;9:185-198. doi: 10.2147/BCTT.S115600. eCollection 2017. Breast Cancer (Dove Med Press). 2017. PMID: 28356768 Free PMC article.

10

Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer.

Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N. Tinholt M, et al. Among authors: sahlberg kk. Oncoimmunology. 2020 Sep 29;9(1):1824644. doi: 10.1080/2162402X.2020.1824644. Oncoimmunology. 2020. PMID: 33457104 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page